Recently, the mTOR inhibitor everolimus was approved for the treatment of slow-growing TSC tumors in the CNS [47], and its predecessor sirolimus was shown to modulate AML and LAM [48], [49]. Here, MTOR is linked to acute myeloid leukemia.